Skip to main content
Publications
Sanguesa J, Sunyer J, Garcia-Esteban R, Abellan A , Esplugues A, Garcia-Aymerich J, Guxens M, Irizar A, Julvez J, Luque-Garcia L, Rodriguez-Dehli AC, Tardon A, Torrent M, Vioque J, Vrijheid M, Casas M. Prenatal and child vitamin D levels and allergy and asthma in childhood . Pediatr Res. 2023 May;93(6):1745-51. doi: 10.1038/s41390-022-02256-9.
Pascal R, Crovetto F, Casas I, Youssef L, Trilla C, Larroya M, Cahuana A, Boada D, Foraster M , Llurba E, Sunyer J, Crispi F, Gratacos E, Gomez-Roig MD. Impact of the COVID-19 pandemic on maternal well-being during pregnancy . J Clin Med. 2022 Apr 15;11(8):2212. doi: 10.3390/jcm11082212
Vilanova MB, Franch-Nadal J, Falguera M, Marsal JR , Canivell S, Rubinat E, Miro N, Mollo A, Mata-Cases M, Gratacos M, Castelblanco E, Mauricio D. Prediabetes is independently associated with subclinical carotid atherosclerosis: an observational study in a non-urban Mediterranean population . J Clin Med. 2020 Jul 7;9(7):2139. doi: 10.3390/jcm9072139
Koziel M, Mazurek M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Rothman KJ , Brandes A, Paquette M, Zint K, Franca LR, Lu S, Bartels DB, Huisman MV, Lip GYH. Persistence with anticoagulation for atrial fibrillation: report from the GLORIA-AF Phase III 1-year follow-up . J Clin Med. 2020 Jun 23;9(6):1969. doi: 10.3390/jcm9061969
Casas M, Forns J , Martinez D , Guxens M, Fernandez-Somoano A, Ibarluzea J, Lertxundi N, Murcia M, Rebagliato M, Tardon A, Sunyer J, Vrijheid M. Maternal pre-pregnancy obesity and neuropsychological development in pre-school children: a prospective cohort study . Pediatr Res. 2017 Oct;82(4):596-606. doi: 10.1038/pr.2017.118
Yosipovitch G, Reaney M, Mastey V, Eckert L, Nelson L , Clark M , Abbe A, Ardeleanu M, Radin A, Gadkari A. Validation of the peak pruritus numerical rating scale: results from clinical studies of dupilumab in adults with moderate-to-severe atopic dermatitis . Poster presented at the 2017 American Academy of Dermatology Annual Meeting; March 4, 2017. Orlando, FL. [abstract] J Am Acad Dermatol. 2017 Jun; 76(6 Suppl 1):AB278. doi: 10.1016/j.jaad.2017.04.1082
Strober B, Gottlieb AB, Sherif B , Mollon P, Gilloteau I, McLeod L , Fox T, Mordin M , Gnanasakthy A , Papavassilis C, Lebwohl MG. Secukinumab sustains early patient-reported outcome benefits through 1 year: results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept . J Am Acad Dermatol. 2017 Apr;76(4):655-61. doi: 10.1016/j.jaad.2016.11.043
Boucher O, Julvez J, Guxens M, Arranz E, Ibarluzea J, Sanchez de Miguel M, Fernandez-Somoano A, Tardon A, Rebagliato M, Garcia-Esteban R , O’Connor G, Ballester F, Sunyer J. Association between breastfeeding duration and cognitive development, autistic traits and ADHD symptoms: a multicenter study in Spain . Pediatr Res. 2017 Mar;81(3):434-42. doi: 10.1038/pr.2016.238
Strober B, Blauvelt A, Zhao Y, Milutinovic M, Mollon P, You R, Sherif B , Williams N, Fox T, Augustin M, Lebwohl M. Secukinumab treatment provides more effective relief from patient-reported psoriasis-related pain, itching, and scaling than ustekinumab . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB273. Previously presented at the 24th European Academy of Dermatology and Venereology Congress. doi: 10.1016/j.jaad.2016.02.1054
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M , Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1049
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B , Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1050
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B , McLeod L , Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1051
Blauvelt A, Korman N, Mollon P, Zhao Y, Milutinovic M, You R, Sherif B , Williams N, Fox T, Augustin M. Secukinumab treatment provides faster and more effective relief from patient-reported quality-of-life impact than ustekinumab in subjects with moderate to severe plaque psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5[S1]):AB273. Previously presented at the 24th European Academy of Dermatology and Venereology Congress. doi: 10.1016/j.jaad.2016.02.1053
Kimball AB, Rothman KJ , Kricorian G, Pariser D, Yamauchi PS, Menter A, Teller CF, Aras G, Accortt NA, Hooper M, Rice KC, Gelfand JM. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results . J Am Acad Dermatol. 2015 Jan;72(1):115-22. doi: 10.1016/j.jaad.2014.08.050